Activity for Alzheimer's Patient: What You Can Do

Planning an activity for an Alzheimer's patient (or patients) can be difficult. You have to keep in mind that because of their condition, it can be difficult for them to perform tasks that you would find simple. However, Alzheimer's statistics have found that, by having patients participate in activities, you can actually slow the progress of the disease in the brain because you are encouraging positive thinking and happiness within the mind of the patient. Assuming you are a caregiver, this article on Alzheimer's is intended to show you some things you can do to make life easier for the person you are caring for.

A Simple Activity is Always Best

Although the cause of Alzheimer's is unknown, the effects are very apprehensive. Alzheimer's is a mental disease, not a physical disease, meaning that patients are physically capable of performing activities. Additionally, Alzheimer's patients retain a childlike intelligence, meaning that they are capable of performing tasks that children can perform.

Caregivers should try to find out what the patient likes to do and design activities around their interests. For example, if the patient you are caring for enjoyed cooking before the disease set in, you should let them cut cookies with you, or make simple dishes (such as made-from-a-box cakes or salads). If your patient enjoys gardening, let them weed or spade a garden. Perhaps you should let them play with toys or games, like building Lego's or playing bingo.

It is important to keep in mind that a patient probably will not want to stay on a task for a very long period of time, but you should constantly encourage your patient, as they need that positive reinforcement to make their lives seem more full. You do not want your patient thinking that they are a burden because it will only encourage the disease to progress more quickly.

Other Things to Keep in Mind as an Alzheimers Caregiver

Always make sure that your patient is taking their medication; this can not be stressed enough. Each day, the disease will get worse and worse if proper care is not given. Additionally, you should research a good Alzheimer's diet. The Alzheimer's foundation has found that a diet consisting of low fat and low cholesterol meals slows the progress of this disease and, for those who do not have Alzheimer's, this type of dietary habit can aid in preventing Alzheimer's.

Also, consider supplements such as turmeric or glyconutrients. Both of these supplements have been statistically found to aid in the slowing of Alzheimer's, which is always a positive benefit. Finally, make sure that your patient is receiving proper amounts of nutrition, as they are not always capable of performing this task on their own.

Being a caregiver for an Alzheimer's patient can be a very exhausting task, I understand that. However, if you take on this responsibility, you must make sure that you are doing everything you can for them. If you follow the advice listed in this article, you will be a good caretaker.

Share Activity Lifted for UnitedHealth Group Incorporated (UNH)

Key Statistics

UnitedHealth Group Incorporated (UNH) escalated 0.4% and closed its last trading session at $210.22. Its opening price on the last trading day was $209.39. The company’s market cap is $202.65 Billion. The company has 964 Million shares outstanding and 951.74 Million shares were floated in market. The short ratio in the company’s stock is documented at 2.86 and the short float is around of 0.88%. UnitedHealth Group Incorporated has been given an analysts’ mean target of 229.26.

52-week High/Low

The highest price UNH stock touched in the last 12 month was $212.77 and the lowest price it hit in the same period was $136.22. Stock’s distance from 52 week High is -1.2% and the distance from 52 week Low is 54.32%.

Share Volume Analysis

A total of 3.7 Billion shares exchanged at hands and its average trading volume is standing at 2.92 Million shares. The relative volume of the stock is 1.27.

Stock Performance

UnitedHealth Group Incorporated (UNH) performance during the last one year upgraded 48.74 percent, while its year to date (YTD) performance showed a positive trend of 31.35 percent. The stock jumped 21.84 percent over the past six months. The stock’s quarterly performance indicates a positive momentum of 8.92 percent, whereas its last one month trend is optimistic with 6.47 percent. Its weekly performance showed upward trend of 0.99 percent.

Profit Margins Analysis

Profitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at 3.9 percent, operating profit margin was 6.8 percent, while gross profit margin stands at 0 percent.

Key Ratios Review

Liquidity ratios help investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 0, current ratio was 0, LT Debt/Equity ratio was 0.61 and Total Debt/Equity ratio stands at 0.74, while Payout ratio is 0.314.

Return on Assets, Investment and Equity

UnitedHealth Group Incorporated (UNH) has a Return on Assets of 5.8 percent, Return on Investment of 11.4 percent and a Return on Equity of 18.8 percent.

Simple Moving Average

Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also helps in determining where it may be possibly heading. Now we look at the Moving Averages, the 200-day is 16.32%, the 50-day is 5.95% and the 20-day is 4.23%.

EPS Growth Analysis

The company’s diluted EPS for trailing twelve months was 8.8.

EPS Estimate for the next year is 10.83.

EPS Estimate for the next Quarter is 2.5.

EPS Growth this year is 20.6 percent.

Earnings and Sales Growth

EPS growth for the next 5 years is 14.88 percent.

Annual EPS growth Past 5 years is 8.9 percent.

Annual Sales Growth in the past 5 years was 12.7 percent.

Quarterly Revenue Growth on year-over-year basis stands at 7.7 percent.

Quarterly Earnings Growth on year-over-year basis stands at 27.8 percent.

Investment Valuation Ratios

The company P/E (price to earnings) ratio is 23.89 and Forward P/E ratio is 19.41. The company P/S (price to Sales) ratio is 1.03, P/B (price to Book) ratio is 4.7, while its P/C (price to Cash) ratio stands at 13.9.

Volatility Analysis

If we look at the Volatility of UnitedHealth Group Incorporated (UNH), Week Volatility is 1.59%, whereas Month Volatility is at 1.74%.

Technical Indicators

UnitedHealth Group Incorporated (UNH)’s RSI (Relative strength index) is at 64.66, its ATR (Average True Range) value is 3.67, while its Beta factor was calculated at 0.64.

Earnings Released Date

The company last reported its quarterly results on Oct 17 BMO.

Analysts Recommendation

UnitedHealth Group Incorporated (UNH) has an Analysts’ Mean Recommendation of 1.5.

Insider Ownership and Transactions

UnitedHealth Group Incorporated’s insider ownership stands at 0.5 percent, while its insider transaction is -2.73 percent.

Institutional Ownership and Transactions

Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. UnitedHealth Group Incorporated’s institutional ownership is 89.1%, while its institutional transactions stand at -0.15%.

Translarna Improved Activity Measures in Phase 3 Trial, But Insignificantly

PTC Therapeutics shared additional data from a Phase 3 trial of Translarna (ataluren), showing that the treatment slightly slowed disease progression in ambulatory boys with Duchenne muscular dystrophy.

The data was presented at the recent American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting in Phoenix, Arizona.

But although several parameters favored Translarna, the differences from placebo-treated patients were not statistically significant.

The presented data was an analysis of the ACT DMD Phase 3 trial, (NCT01826487), which assessed Translarna’s effectiveness and safety in 228 Duchenne patients with so-called nonsense mutations in their dystrophin gene.

Nonsense mutations introduce a stop signal — read by the protein-making machinery — in a gene. This mutation leads to the production of a truncated, and nonfunctional, form of dystrophin. Translarna works by bypassing the stop sign to produce a functional dystrophin protein.

Researchers assessed how well study participants moved using the North Star Ambulatory Assessment (NSAA), which is a tool developed specifically to measure disease progression in Duchenne patients who are still able to walk.

The NSAA scores a variety of activities, ranging from standing up from a chair to jumping. Each activity can be given a score of 0, 1, or 2, with low numbers representing a poorer function.

The presentation, “Results of North Star Ambulatory Assessments in the Phase 3 Ataluren Confirmatory Trial in Patients With Nonsense Mutation Duchenne Muscular Dystrophy,” showed that over the 48 weeks of the trial, Translarna-treated patients had an average score reduction of 7.0. Those who received placebo worsened by 8.5 points — making a difference of 1.5 points between the groups.

Researchers also reported that fewer patients in the Translarna group shifted from a score of 1 or 2, which signified they were able to perform the activity, to 0 or an inability to perform. This was seen across all 17 functions tested, researchers said.

Looking at individual function tests, Translarna-treated patients consistently performed better, with differences ranging between 1 percent for lifting head, to 12 percent for rising from a chair.

The U.S. Food and Drug Administration (FDA) is reviewing the marketing application for Translarna, and is expected to reach a conclusion by Oct. 24, 2017. But the outcome of the review is far from clear.

In 2016, the FDA rejected a new drug application (NDA) for Translarna because of an incomplete application. In March 2017, PTC applied again. The FDA has called PTC to a meeting, scheduled Sept. 28, to discuss the application.

But the NDA builds on data from a trial — ACT DMD — that failed to show a statistical difference in its primary outcome measure of the 6-minute walk test (6-MWT). The test, which assesses exercise tolerance, showed that Translarna-treated boys performed on average 15 meters more than their placebo-treated peers at the end of the study.

While this difference was too subtle to be considered statistically significant, U.S. regulators still agreed to review the data. The willingness to accept the application might be tied to Translarna’s better efficiency in a subgroup of patients who could walk 300–400 meters in the 6-MWT when the trial began. In this group, Translarna-treated boys performed on average 47 meters more than those receiving a placebo — a difference considered statistically significant.

Meanwhile, however, PTC needs to perform another trial to provide more data. This long-term study (NCT03179631) is ongoing.

European regulators adopted a different approach to the drug. Translarna is conditionally approved for Duchenne patients, five years or older. While the approval was renewed in January, its continuing approval is dependent on data from the long-term trial, which is expected to complete in 2021.

Needle Action Activity Spotted in UnitedHealth Group Inc (UNH) – Concord Register

Needle moving action has been spotted in UnitedHealth Group Inc (UNH) as shares are moving today on volatility -0.27% or $-0.53 from the open. The NYSE listed company saw a recent bid of $194.21 and 278230 shares have traded hands in the session.

Investors are typically trying to find solid stocks to add to the portfolio. When it comes to stock picking, there is no magic formula. There are various techniques that may provide better outcomes than others, but it’s how these techniques are put together and applied that can make all the difference. One of the keys to successful investing is the proper use of information. Everyone can see the vast amount of data that is available on publically traded companies. Being able to interpret the data could end up being the most important factor when it comes to successfully selecting stocks to buy. Taking the time to investigate a particular stock that looks attractive can be a smart move. Investors may be better served to not just jump on the hot stock of the day, but employ analysis that may help uncover some buried information. Good stocks are indeed out there, it may just take some time to figure out which ones they are.

Now let’s take a look at how the fundamentals are stacking up for UnitedHealth Group Inc (UNH). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. UnitedHealth Group Inc currently has a yearly EPS of 8.32. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.

Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. UnitedHealth Group Inc (UNH) currently has Return on Equity of 19.84. ROE is a ratio that measures profits generated from the investments received from shareholders.

In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further to see why profits aren’t being generated from shareholder money.

Another ratio we can look at is the Return on Invested Capital or more commonly referred to as ROIC. UnitedHealth Group Inc (UNH) has a current ROIC of 11.38. ROIC is calculated by dividing Net Income – Dividends by Total Capital Invested.

Similar to ROE, ROIC measures how effectively company management is using invested capital to generate company income. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite.

Turning to Return on Assets or ROA, UnitedHealth Group Inc (UNH) has a current ROA of 6.38. This is a profitability ratio that measures net income generated from total company assets during a given period. This ratio reveals how quick a company can turn it’s assets into profits. In other words, the ratio provides insight into the profitability of a firm’s assets. The ratio is calculated by dividing total net income by the average total assets.

A higher ROA compared to peers in the same industry, would suggest that company management is able to effectively generate profits from their assets. Similar to the other ratios, a lower number might raise red flags about management’s ability when compared to other companies in a similar sector.


JAIL ACTIVITY: July 17, 2017 | Clark County

CLARK COUNTY

BOOKED-IN

William Lawrence Price, 35, Indianapolis, warrant

Raymone Akeem Passmore, 28, Indianapolis, warrant

Jon Anthony Pierson, 57, Indianapolis, warrant

Crystal Danielle Wrighthouse, 33, Clarksville, warrant

Tammy Ann Wingate, 54, Cuvrun, Ky., warrant

Lindsey John Stroop, 29, Charlestown, hold for other agency

James Lowayne Gray, 52, Jeffersonville, warrant

Danny L. Myers Jr., 25, Clarksville, hold for other agency

Lisa A. Rice, 36, Clarksville, possession of synthetic drug/synthetic drug look-a-like substance

Michael Aaron Wagner, 29, New Albany, warrant

Aimee Gayle Bottoms, 31, Clarksville, dealing/manufacturing in methamphetamine, possession of syringe

Robert Edward Stringer, 40, Jeffersonville, dealing/manufacturing in methamphetamine, possession of syringe, possession of paraphernalia, hold for Floyd County

Gage Evan England, 22, Clarksville, warrant

Joshua Allen Roberts, 30, Jeffersonville, warrant

Cassidy Diane Grider, 34, Louisville, theft

Joy Lynn Byerly, 29, Jeffersonville, warrant

Allison Mae Crase, 85, Corydon, resisting law enforcement, possession of controlled substance, possession or use of Legend Drug or Precursor

Katie Lynn McFarland, 19, New Albany, illegal possession of alcohol, driving while intoxicated

Lamon William Robinson, 29, Louisville, driving while intoxicated

Kendell Brian Warren, 26, New Albany, warrant

Maurice DeBois Gassaway, 44, Louisville, possession of marijuana, hash oil, hashish or spice

Julie Anne Ballard, 53, Clarksville, theft

Steven Wayne Keller, 27, Memphis, warrant

Amanda Lee Campbell, 29, Jeffersonville, warrant

Nicholas Jamar Smith, 27, Louisville, visiting a common nuisance, drugs, possession of marijuana, hash oil, hashish or spice

Blake Anthony McLain, 28, Jeffersonville, warrant

William David Jones Jr., 34, Jeffersonville, warrant

Natalie Sue Harris, 33, no address listed, warrant

Fernando Ustabio Cobon-Matias, 30, Corydon, leaving accident scene, driving while intoxicated, operator never licensed

Fila Monee Cornelius, 28, Jeffersonville, warrant

Jason Allen Morrow, 33, Louisville, invasion of privacy, criminal trespass

Ramiro Rojas, 36, New Albany, operator never licensed

Darrell Robert LaFountain, 29, Jeffersonville, possession or use of Legend Drug or Precursor, possession of marijuana, hash oil, hashish or spice, resisting law enforcement

Brian Herrera, 19, Fairdale, Ky., operator never licensed

Catherine Ann Wise, 33, New Albany, court order return

Justin Daniel Vaughn, 38, New Albany, warrant

Anthony M. Been, 28, New Albany, warrant

RELEASED

Wendi Diandra Baili Cook, 27, Sellersburg, driving while suspended

Emily Michelle Egler, 32, Atlanta, battery, resisting law enforcement, public intoxication, disorderly conduct

Andrea Jane Haymaker, 54, Floyds Knobs, possession of methamphetamine, possession of paraphernalia, possession of marijuana, hash oil, hashish or spice, resisting law enforcement, theft, criminal trespass, driving while suspended

James Shirley Dickerson, 29, Louisville, dealing cocaine or narcotic, neglect of dependent, carrying handgun without license

Isaac Donald Corum, 20, Charlestown, illegal possession of alcohol, battery with bodily injury

Demond Terrell Conner, 37, Jeffersonville, driving while suspended

Michael Ryan Burke, 52, Jeffersonville, driving while intoxicated, public indecency

Christina L. Trent, 35, Jeffersonville, battery with bodily injury

Gerald Thomas King, 52, Jeffersonville, driving while intoxicated, carrying handgun without license

Theresea Michelle Higdon, 29, Jeffersonville, possession of a controlled substance, maintaining a common nuisance, possession of marijuana, hash oil, hashish, hashish or spice, possession or use of Legend drug or Precursor, possession of paraphernalia

Lindsey Parker, 26, Jeffersonville, possession of a controlled substance, possession of marijuana, hash oil, hashish or spice, possession of paraphernalia

Moses Dusaber Ndagije, 25, Louisville, driving while intoxicated

Elizabeth Ann Stamper, 29, Shepherdsville , Ky., battery with bodily waste, resisting law enforcement, disorderly conduct, public intoxication

FLOYD COUNTY

BOOKED-IN

Misdemeanors

Francis R. Duerr III, 40, New Albany, public intoxication

Andrew L. Wilfong, 31, Georgetown, public intoxication

Joseph R. Collins, 21, New Albany, operating a vehicle without ever receiving a license

James J. Martell, 27, New Albany, warrant, theft

Bryce A. Shirley, 19, Jeffersonville, theft, minor consumption of alcohol

Jeremy J. Burks, 27, New Albany, warrant, possession of marijuana

Jeffrey G. Keithley, 46, Borden, public intoxication

Nicholas R. Bethards, 34, city at-large, trespass, possession of a controlled substance

Felonies

Michael S. Haas, 33, Georgetown, maintaining a common nuisance, possession of methamphetamine, possession of a syringe, possession of marijuana, possession of paraphernalia, dealing methamphetamine

Amanda R. Sommers, 38, Austin, driving while suspended prior, possession of methamphetamine, maintaining a common nuisance

Christopher S. Etheridge, 25, Hodgenville, Ky., theft

Derek A. Lane, 32, city at-large, invasion of privacy, criminal trespass, possession of a controlled substance, intimidation

Brayden A. Dannenfelser, 26, Floyds Knobs, warrant, intimidation, battery against a public safety official, public intoxication

Dorothy D. Ruby, 33, Georgetown, warrant, unlawful possession of a syringe

Lori A. Cochran, 43, Corydon, maintaining a common nuisance, possession of methamphetamine, possession of syringe, possession of marijuana, possession of paraphernalia

Scott J. Lindig, 41, Georgetown, maintaining a common nuisance, possession of methamphetamine, possession of syringe, possession of marijuana, possession of paraphernalia, dealing in methamphetamine

RELEASED

Misdemeanors

Dylon L. Tindle, 19, Floyds Knobs, operating while intoxicated, minor consumption of alcohol

Scott A. Lehman, 54, New Albany, warrant, operating while intoxicated

Justin D. Vaughn, 38, New Albany, possession of paraphernalia prior

Jeffery A. Davis Jr., 30, Sulfer, leaving scene of an accident

Samuel J.F. Windell, 18, Georgetown, possession of marijuana, possession of paraphernalia

Abigail M. Spears, 21, Clarksville, driving while suspended

McKenzie T. Mycio, 24, New Albany, operating while intoxicated in manner that endangers

Austin R. Jarrell, 21, Jeffersonville, warrant, driving while suspended

Felonies

Michael L. Nelson, 42, Jeffersonville, warrant, possession of methamphetamine, maintaining a common nuisance, possession of marijuana